Experimental combo aims to rev up immune system against Hard-to-Treat prostate cancer
NCT ID NCT05445609
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining two drugs—vidutolimod and nivolumab—can help the immune system attack metastatic castration-resistant prostate cancer. Nivolumab blocks a protein that shuts down immune cells, while vidutolimod is designed to train those cells to target tumors. The study planned to enroll 10 men whose cancer had progressed after other treatments, but it is currently suspended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vidutolimod (CMP-001) and nivolumab
What this could lead to
If it works, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong
This is a very small, early-phase trial (only 10 participants) and is currently suspended. The treatment may not shrink tumors or improve survival, and side effects from immune therapy can be severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States